Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (Kremezin™) in cancer patients

  • Authors:
    • Yorinobu Maeda
    • Terumasa Ohune
    • Mamoru Nakamura
    • Miho Yamasaki
    • Yoshie Kiribayashi
    • Teruo Murakami
  • View Affiliations

  • Published online on: September 1, 2004     https://doi.org/10.3892/or.12.3.581
  • Pages: 581-585
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Irinotecan (CPT-11) treatments induce severe diarrhoea at a rate of >40%. In clinical trials, we evaluated the preventing effects of oral alkalization, which has been reported previously, and oral carbonaceous adsorbent (Kremezin™) on diarrhoea possibly induced by CPT-11. Evaluation was made by counting the maximum number of bowel motions in each patient. Five patients out of 7 treated with CPT-11 had bowel motions of >5 times daily, and maximum number of bowel motions reached 20 times in 1 patient. Oral alkalization (2 g sodium bicarbonate, 2 g magnesium oxide and 300 mg ursodeoxycholic acid daily for 4 days) decreased bowel motions from 20 to 8 thereafter in the patient. Maximum number of bowel motions in other 3 patients treated in a combination of CPT-11 and oral alkalization was <3. Oral adsorbent (2 g Kremezin x 3 times, during and after CPT-11 treatment) also decreased maximum number of bowel motions from 7 (without oral adsorbent) to 3 in 1 patient. Also, the maximum number of bowel motions in other 3 patients treated with oral adsorbent was <3 (p<0.05, vs CPT-11 alone). Effect of oral Kremezin on plasma concentrations of CPT-11 and its related compounds after a 1-h CPT-11 infusion, evaluated in a patient, was small. These results suggested that the oral Kremezin is effective in ameliorating CPT-11-induced diarrhoea without decreasing much the plasma clearance of CPT-11.

Related Articles

Journal Cover

September 2004
Volume 12 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Maeda Y, Ohune T, Nakamura M, Yamasaki M, Kiribayashi Y and Murakami T: Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (Kremezin™) in cancer patients. Oncol Rep 12: 581-585, 2004.
APA
Maeda, Y., Ohune, T., Nakamura, M., Yamasaki, M., Kiribayashi, Y., & Murakami, T. (2004). Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (Kremezin™) in cancer patients. Oncology Reports, 12, 581-585. https://doi.org/10.3892/or.12.3.581
MLA
Maeda, Y., Ohune, T., Nakamura, M., Yamasaki, M., Kiribayashi, Y., Murakami, T."Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (Kremezin™) in cancer patients". Oncology Reports 12.3 (2004): 581-585.
Chicago
Maeda, Y., Ohune, T., Nakamura, M., Yamasaki, M., Kiribayashi, Y., Murakami, T."Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (Kremezin™) in cancer patients". Oncology Reports 12, no. 3 (2004): 581-585. https://doi.org/10.3892/or.12.3.581